사일렉스 홀딩 컴퍼니(SCLX)는 NASDAQ에 상장된 Healthcare · Drug Manufacturers - General 기업입니다. 현재가 $6.76 (+0.30%), 시가총액 $0.04B, 52주 범위 $4.55 ~ $30.00.
Scilex Holding Company focuses on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. Its commercial products include ZTlido (lidocaine topical system) 1.8% (ZTlido), a prescription lidocaine topical product for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a ready-to-use oral solution for the acute treatment of migraine with or without aura in adults; and GLOPERBA, a liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults. The company also develops three product candidates,
사일렉스 홀딩 컴퍼니의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 BlackQuant에서 실시간으로 확인할 수 있습니다.
사일렉스 홀딩 컴퍼니의 현재 주가는 $6.76 (+0.30%)입니다. BlackQuant에서 실시간 시세와 차트를 확인할 수 있습니다.
사일렉스 홀딩 컴퍼니의 시가총액은 약 $0.04B입니다.
Scilex Holding Company focuses on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. Its commercial products include ZTlido (li